1789 TT

ScinoPharm Investor Conference

— 2024 12 12

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Company Overview

02 Business Update

03 Financial Performance



Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 77 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 954 active DMFs worldwide with 67 US DMFs*
- 200+ contract projects with 13 approved/launched (11 NCEs) and 4 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority. In November 2024, we passed Brazilian ANVISA 1st on-site GMP inspection with zero defect and maintained its exceptional track record of 5 consecutive zero defect inspections by the US FDA
- Injectable plant certified by US FDA and TFDA

*As of 2024/10/31



Business Updates

2024 Anticipated Approvals and Strategic Focus

Type	Product	Region	Indication	Brand Marketer	Regional * Sales (Mil., USD)
Generic API	Cladribine	CN(✓)	Multiple Sclerosis	Merck	5
Generic API	Olaparib	CN(✓)	Cancer	AstraZeneca	129
Generic API	Exemestane	CN(✓)	Breast Cancer	Pfizer	246
Generic API	Azacitidine	EU	Myelodysplastic syndromes	Celgene	384
Generic API	Dantrolene Na	EU	Malignant Hyperthermia	Eagles	11
CDMO API	Galantamine Benzoate Gluconate	US(✓)	Alzheimer's disease	Post-marketing Disclosure	NA
CDMO API	Eflornithine HCl	US/EU	Familial Adenomatous Polyposis	Post-marketing Disclosure	NA
CDMO API	Eflornithine HCl	EU	Neuroblastoma	Post-marketing Disclosure	NA
Generic Drug	Clofarabine	US	Acute Lymphoblastic Leukemia	Genzyme	3

✓ : Approved / As of 2024/10/31

* Source : IQVIA Data (2023Q1-2023Q4)

Strengthening Core API Product Contributions

- **Reinforcing our core API products by expanding key offerings, optimizing production costs to remain competitive in the markets, and increasing sales volume to extend our API foundation**



Expanding CDMO Services

- **Focusing on our expertise in peptides, steroids, and cytotoxic products, we are leveraging our R&D capabilities to secure collaboration opportunities, thereby broadening the scope of our contract development services**



Drug Product Business Development

- **We are continuously expanding our injectable formulation product portfolio, aligning with our goal of providing vertical integration from API development to finished dosage forms**

Dosage Form	Project Numbers	Indication	Under Development	Technical Package Ready	Dossier Ready	Under Registration	Approved
Lyophilized Powder	4	• Myelodysplastic Syndromes • Multiple Myeloma • Oncology		1 1			1 1
Liquid Solution	6	• Leukemia • Oncology • Reversal of Neuromuscular Blockade		 4 1		1	
Prefilled Syringe	3	• Thromboembolic Disorders • Multiple Sclerosis • Medical Imaging Agents		 1		1	1
Cartridge in Device	4	• Osteoporosis • Diabetes Mellitus • Chronic Weight Management	1		1	1 1	

In-House Drug Product Status



Two in-house cartridge products submitted ANDA to FDA, and another one is preparing registration batch production

A product passed Pre-Approval Inspection with zero FDA-483 Form issued in Apr., 2024

*Preparing for response to FDA CRL / **Responded to FDA CRL

China Business

- Leveraging the strengths of our Tainan and Changshu facilities, we are deepening our presence in the Chinese market, which is now entering a growth phase
- The Changshu plant, recognized for its flexible production support and strategic positioning in the Chinese market, achieved profitability in 2023 and is on a continued growth trajectory in 2024
- In March 2024, the Changshu facility underwent another FDA inspection, successfully passing with zero deficiencies (Zero Form 483), demonstrating our high standards of operation and enhancing our appeal to international companies and "dual filing" clients in the U.S. and China
- We have passed GMP compliance inspections for five products, which are now in full-scale commercial productions and supplies, with additional products progressing through the pipeline

Product	Indication	Sales in China*
Sodium Phenylbutyrate	Urea cycle disorders	Orphan disease medicine
Donafenib	Advanced liver cancer Thyroid cancer	c. USD 24.5 million
Bimatoprost	Glaucoma	c. USD 1.9 million
Azilsartan	Hypertension	c. USD 6.5 million
Olaparib	Cancer	c. USD 129 million

* Source：IQVIA Data (2023Q1-2023Q4)



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	3Q 2024		YoY	3Q 2023	
Revenue	2,370	100%	15%	2,063	100%
Gross Profit	923	39%	22%	758	37%
Operating Expenses	(668)	(28%)	5%	(635)	(31%)
Operating Profit	255	11%	107%	123	6%
Net Profit before Tax	299	13%	90%	158	8%
Net Profit after Tax	242	10%	87%	130	6%
EPS (NTD)	0.31	-	-	0.16	-

Sales Distribution – By Business





Unit: USD/M

	Generic API	CDMO	Drug Product
3Q 2024 Sales	46.6	19.1	8.4
YoY	0.4%	42.5%	22.6%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
3Q 2024 Sales	47.0	17.6	9.5
YoY	6.0%	34.1%	3.4%

Sales Distribution – By Region



Unit: USD/M

	US & Canada	EU	Japan	India	China	Others
3Q 2024 Sales	14.4	14.6	9.9	10.1	13.8	11.3
YoY	35.8%	6.2%	-14.0%	-15.5%	55.9%	13.0%

Consolidated Balance Sheet

NTD Million	2024/09/30		2023/09/30	
Cash and Cash Equivalents	3,976	34%	3,995	35%
Accounts Receivable	446	4%	364	3%
Inventories	1,876	16%	1,643	14%
Property, Plant & Equipment	3,702	32%	3,652	32%
Other Current/Non-Current Assets	1,784	14%	1,913	16%
Total Assets	**11,784**	**100%**	**11,567**	**100%**
Financial Debt	36	0%	58	1%
Other Current Liabilities	658	6%	638	5%
Other Non-Current Liabilities	650	5%	629	5%
Total Liabilities	**1,344**	**11%**	**1,325**	**11%**
Total Shareholders' Equities	**10,440**	**89%**	**10,242**	**89%**

Consolidated Cash Flow Statement

NTD million	3Q 2024	3Q 2023	Dif.
From Operating Activities	**496**	**172**	**324**
Depreciation & Amortization	365	344	21
From Investing Activities	**(234)**	**(157)**	**-77**
Capital Expenditure	(241)	(209)	-32
From Financing Activities	**(242)**	**(313)**	**71**
Effect of foreign exchange rate changes	**14**	**(2)**	**16**
Net Change in Cash	**34**	**(300)**	**334**
Beginning Balance	**3,942**	**4,295**	**-353**
Ending Balance	**3,976**	**3,995**	**-19**



Q & A

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT